Request Study Information

After you submit your request, a staff member will contact you.There’s no obligation and our team is here to help you decide on a study that’s best for you.

Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring

The primary purpose of this study is to utilize the FSL3 to help prolong the length of time people with diabetes maintain adherence to GLP-1 and GIP/GLP-1 antagonists. Subjects with type 2 diabetes who are newly beginning glucagon-like peptide 1 (GLP-1) and dual gastric inhibitory polypeptide/glucagon-like peptide 1 (GIP/GLP-1) agonist therapy will be assigned to use either the FSL3 or their existing Standard of Care (SOC) device to manage their type 2 diabetes. Effectiveness will be characterized by assessing the length of time subjects in each group remain on a GLP-1 or GLP-1/GIP combination drug. 

Enter Your Information

(All fields are required)

Study Request Form (specific)

Name(Required)
Date of Birth(Required)
Race(Required)
Select one or more options that best describe you. This information can help ensure that all populations are represented in research.

By entering your email address and/or phone number on this form, you represent that you are at least 18 years of age and consent to receiving communications (e.g., call, SMS, text, and/or email) from ECIR and/or the research site(s) involved with the clinical trials that appear on this website. Messaging frequency varies. Message and data rates may apply. You may reply with STOP to a text message. For any help regarding messaging, please email us at [email protected]. For full details, refer to ECIR’s privacy policy and website terms of use. Submissions on this website are not monitored 24/7. Do NOT submit personal health or medical information on this form. If you are enrolled in a trial and have questions, please call your research site.